3,5-dimethyltyrosine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3,5-dimethyltyrosine
• 英文别名: (2S)-2-azaniumyl-3-(4-hydroxy-3,5-dimethylphenyl)propanoate
• 化学式: C₁₁H₁₅NO₃
• 分子量: 209.245
• InChiKey: DFQINAKFXBIFHG-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  S-腺苷-L-蛋氨酸 、 3-甲基-L-酪氨酸 在 tyrosine C methyltransferase 作用下， 以 aq. phosphate buffer 为溶剂， 生成 3,5-dimethyltyrosine
  参考文献：
  名称：

  WO2023/182469

  摘要：

  公开号：

文献信息

• AROMATIC-CATIONIC PEPTIDES AND USES OF SAME
  申请人：Szeto Hazel H.

  公开号：US20120329730A1

  公开（公告）日：2012-12-27

  The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

  该披露提供了芳香性阳离子肽组合物以及使用这些组合物预防或治疗疾病的方法。该方法包括向需要的对象施用有效量的芳香性阳离子肽。
• [EN] AROMATIC-CATIONIC PEPTIDES CONJUGATED TO ANTIOXIDANTS AND THEIR USE IN TREATING COMPLEX REGIONAL PAIN SYNDROME<br/>[FR] PEPTIDES AROMATIQUES-CATIONIQUES CONJUGUÉS À DES ANTIOXYDANTS ET LEUR UTILISATION DANS LE TRAITEMENT D'UN SYNDROME DOULOUREUX RÉGIONAL COMPLEXE
  申请人：SCHILLER PETER

  公开号：WO2017093897A1

  公开（公告）日：2017-06-08

  Compositions comprising an antioxidant directed or indirectly conjugated to an aromatic-cationic peptide are provide. Said antioxidants are selected from TEMPO, Tro, PBN, AHDP, DBHP, Caf and Hem and may be conjugated to the aromatic-cationic peptide directly or indirectly via a linker to the N-terminus, C-terminus or a side chain of an amino acid residue of the aromatic-cationic peptide. In some embodiments, the aromatic-cationic peptide is 2',6'-Dmt-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2 or D-Arg-2',6'-Dmt-Lys-Phe-NH2. These conjugates have increased antioxidant activity as compared to the unconjugated aromatic-cationic peptide and have utility in treating complex regional pain syndrome.

  提供了包含直接或间接与芳香-阳离子肽结合的抗氧化剂的组合物。所述抗氧化剂从TEMPO、Tro、PBN、AHDP、DBHP、Caf和Hem中选择，并且可以通过连接剂直接或间接地与芳香-阳离子肽结合到N-末端、C-末端或芳香-阳离子肽的氨基酸残基的侧链。在某些实施例中，芳香-阳离子肽为2',6'-Dmt-D-Arg-Phe-Lys-NH2、Phe-D-Arg-Phe-Lys-NH2或D-Arg-2',6'-Dmt-Lys-Phe-NH2。与未结合的芳香-阳离子肽相比，这些共轭物具有增强的抗氧化活性，并可用于治疗复杂性区域性疼痛综合征。
• Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells
  申请人：Ordway Research Institute, Inc.

  公开号：EP2662079A1

  公开（公告）日：2013-11-13

  Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone antagonists and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone antagonists and/or nanoparticulate or polymeric forms thereof.

  公开了使用甲状腺激素拮抗剂和/或其纳米粒子或聚合物形式来增加正常和/或化疗耐药肿瘤或癌细胞的化疗敏感性的方法。还公开了使用甲状腺激素拮抗剂和/或其纳米粒子或聚合物形式来增加正常和/或放射治疗耐药肿瘤或癌细胞的放射敏感性的方法。
• USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS
  申请人：Davis Paul J.

  公开号：US20120315320A1

  公开（公告）日：2012-12-13

  Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.

  本发明揭示了使用甲状腺激素类似物及其纳米粒子或聚合物形式，增加正常和/或化疗耐药肿瘤或癌细胞的化疗敏感性的方法。本发明还揭示了使用甲状腺激素类似物及其纳米粒子或聚合物形式，增加正常和/或放射线耐药肿瘤或癌细胞的放射线敏感性的方法。
• Methods for Reducing CD36 Expression
  申请人：Szeto H. Hazel

  公开号：US20070129306A1

  公开（公告）日：2007-06-07

  The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t −1, except that when a is 1, p t may also be 1.

  该发明提供了一种减少细胞中CD36表达的方法。该方法包括使用一种至少具有一个净正电荷的芳香-阳离子肽与细胞接触，该肽至少含有四个氨基酸，最多含有约二十个氨基酸，并且具有最小净正电荷数（pm）和氨基酸残基总数（r）之间的关系，其中3pm是小于或等于r+1的最大数；以及最小芳香基团数（a）和净正电荷总数（pt）之间的关系，其中2a是小于或等于pt-1的最大数，但当a为1时，pt也可以为1。